Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Bladder Cancer, November 2026

Free Subscription


Abstracts

Retrieve all available abstracts of the following 263 articles:
HTML format


 

Single Articles

  1. ZHANG W, Zheng K, Peng M, Zhang J, et al
    Comprehensive Characterization of Crotonylation-Related Long Non-Coding RNAs Reveals a Prognostic Signature and Functional Landscape in Bladder Cancer.
    J Environ Pathol Toxicol Oncol. 2026;45:1-23.
    PubMed    
    Abstract available

  2. CHATURVEDI A, Nisam I, Mallya V, Mandal S, et al
    PD-L1 Expression in muscle-invasive bladder carcinoma: correlation with tumor-stroma ratio and clinicopathological parameters.
    Indian J Pathol Microbiol. 2026;69:425-429.
    PubMed    
    Abstract available

  3. PETRY MA, Polakowski CB, Rabito EI, Kool R, et al
    Impact of the Multimodal Protocol on the Outcomes of Cancer Patients Undergoing Radical Cystectomy.
    Rev Col Bras Cir. 2026;53:e2026005826.
    PubMed    
    Abstract available

  4. GU Y, He W, Yu X, Jiang C, et al
    The current landscape of bladder-sparing therapies in BCG-refractory high-risk nonmuscle-invasive bladder cancer.
    Curr Urol. 2026;20:359-367.
    PubMed    
    Abstract available

  5. PEI G, Liang Y, Zhang W, Kang M, et al
    Application of rapidly prepared nonactivated high-efficiency chimeric antigen receptor T cells in the treatment of bladder cancer.
    Curr Urol. 2026;20:379-391.
    PubMed    
    Abstract available

  6. DIAMANTIDIS D, Tsakaldimis G, Smyrlis N, Chousein C, et al
    Explainable artificial intelligence in prostate and bladder cancer: A review of imaging, digital pathology, molecular profiling, and clinical data.
    Curr Urol. 2026;20:332-348.
    PubMed    
    Abstract available

  7. LUO H, Xu C, Liu Y, Yao Y, et al
    Association of MAGEA4 expression with molecular and immune subtypes and clinical outcomes in recurrent bladder cancer.
    Front Oncol. 2026;16:1906141.
    PubMed    
    Abstract available

  8. XU M, Song X, Kudusi, Zu X, et al
    SLCO1B3 is associated with poor survival and promotes bladder cancer progression through Wnt/beta-catenin signaling.
    BMC Med Genomics. 2026;19:165.
    PubMed    
    Abstract available

  9. HE P, Chen R, Zheng Q, Tian M, et al
    Development and validation of a preoperative biparametric MRI-based habitat model for risk stratification of non-muscle-invasive bladder cancer.
    BMC Med Imaging. 2026;26:563.
    PubMed    
    Abstract available

  10. CAO C, Lai Y, Ye W, Wang Z, et al
    DCST1 drives cisplatin resistance via non-canonical ubiquitination and stabilization of NFAT5 to suppress PANoptosis in bladder cancer.
    Cell Death Differ. 2026 Oct 28. doi: 10.1038/s41418-026-01866.
    PubMed    
    Abstract available

  11. LEE HW, Park YH, Kim KH, Jung EH, et al
    Sequential intravesical mitomycin-C and gemcitabine therapy for BCG-unresponsive high-risk non-muscle-invasive bladder cancer: protocol for a prospective, open-label, single-arm, multicentre phase II (IMGeS) study.
    BMJ Open. 2026;16:e117239.
    PubMed    


  12. TSUBOTA S, Kaneko GO, Igarashi D, Takahashi T, et al
    Initial Clinical Experience With Gemcitabine, Cisplatin, and Nivolumab for Advanced Urothelial Carcinoma: A Four-case Series.
    In Vivo. 2026;40:3912-3921.
    PubMed    
    Abstract available

  13. UENO S, Yasuda R, Fujita N, Tsukamoto Y, et al
    Anti-gicerin IgG Reduces Adhesion, Wound Closure and Post-seeding Tumor Burden in T24 Bladder Carcinoma Models.
    In Vivo. 2026;40:3351-3366.
    PubMed    
    Abstract available

  14. HU C, Wang F, Zhang Q, Xu H, et al
    Deep learning-based multiomics integration identifies AI-defined tissue regions associated with cancer-associated fibroblast enrichment and chemoresistance in muscle-invasive bladder cancer.
    Funct Integr Genomics. 2026;26:308.
    PubMed    
    Abstract available

  15. OLA L, Busacca G, Dalmasso E, Ornaghi PI, et al
    Implementation of a same-session outpatient diode laser ablation pathway for suspected recurrent low-grade NMIBC: feasibility, safety, and early outcomes.
    World J Urol. 2026;44:772.
    PubMed    
    Abstract available

  16. COLLINS K, Cheng L
    FGFR Alterations in Bladder Cancer-From Molecular Pathogenesis to Precision Oncology.
    JAMA Oncol. 2026 Oct 29. doi: 10.1001/jamaoncol.2026.4196.
    PubMed    
    Abstract available

  17. OLA L, Busacca G, Dalmasso E, Giordano A, et al
    Real-world diagnostic performance of pre-TURBT multiparametric MRI using VI-RADS for detecting muscle-invasive bladder cancer: A retrospective single-center study.
    Urologia. 2026 Oct 29:3915603261499101. doi: 10.1177/03915603261499101.
    PubMed    
    Abstract available

  18. TONG P, Tu J, Li M, Peng X, et al
    Catheter-Integrated Nanosensors Unmask Bladder Cancer.
    Chem Biomed Imaging. 2026;4:2126-2128.
    PubMed    


  19. WEI Y, Liu Q, Li S, Jia F, et al
    Combined Application of 3D Reconstruction and ICG Fluorescence Imaging in Pelvic Lymph Node Dissection for Bladder Cancer: A Retrospective Study.
    J Endourol. 2026 Oct 28:8927790261502136. doi: 10.1177/08927790261502136.
    PubMed    
    Abstract available

  20. VAN GENNEP EJ, Claps F, KleinJan GH, Bostrom PJ, et al
    The Prognostic Value of Lymphovascular Invasion in Combination with Nodal Stage on Disease-specific Survival in Patients with Bladder Cancer Following Upfront Radical Cystectomy.
    Eur Urol Focus. 2026 Oct 28:S2405-4569(26)00200.
    PubMed    
    Abstract available

  21. XIN LL, Guo JJ, Zheng XY, Li ZY, et al
    Perioperative immunogenomics and clinical outcomes under ERAS-based nursing care in muscle-invasive bladder cancer.
    Front Genet. 2026;17:1967034.
    PubMed    
    Abstract available

  22. MASONE MC
    Urine cfRNA liquid biopsy for bladder cancer.
    Nat Rev Urol. 2026 Oct 27. doi: 10.1038/s41585-026-01211.
    PubMed    


  23. RITTER J, Barker K, Marco T, Rao A, et al
    The Effect of Socioeconomic Inequality as Measured by a Standardized Neighborhood Deprivation Index on the Tumor Microenvironment and Genomics of Bladder Cancer.
    Clin Genitourin Cancer. 2026 Sep 20:102681. doi: 10.1016/j.clgc.2026.102681.
    PubMed    
    Abstract available

  24. ZHUANG R, Wu Z, Zheng R, Chen Y, et al
    Intratumoral Klebsiella pneumoniae drives metabolic-immune remodeling and immunotherapy resistance in bladder cancer.
    J Immunother Cancer. 2026;14:e016574.
    PubMed    


  25. YOU Y, Zhang H, Sun J, Shuai Y, et al
    Non-canonical function of SCIMP restricts JAK1 activity to counteract immune evasion in bladder cancer.
    J Immunother Cancer. 2026;14:e015651.
    PubMed    


  26. WANG H, Wang B, Liu H, Wu J, et al
    PCB-118 increases PDE4D abundance and thermal stability in bladder cancer cells: An integrative toxicogenomic and cellular study.
    Biochem Biophys Res Commun. 2026;841:154810.
    PubMed    
    Abstract available

  27. NUSBAUM DJ, Ferguson JE 3rd, Spiess PE, Li R, et al
    New and Emerging Options for the Treatment of Non-Muscle-Invasive Bladder Cancer.
    J Natl Compr Canc Netw. 2026 Oct 27:e267061. doi: 10.6004/jnccn.2026.7061.
    PubMed    
    Abstract available

  28. YUK HD, Han JH, Jeong SH, Jeong CW, et al
    Perioperative outcomes of intracorporeal versus extracorporeal urinary diversion following robot-assisted radical cystectomy in multicenter KORARC database.
    World J Urol. 2026;44:763.
    PubMed    
    Abstract available

  29. CAGLAYAN D, Goktas E, Somuncu MN, Kilinc F, et al
    FGFR 1-3 Alteration Frequency in Muscle-Invasive Urothelial Bladder Cancer and Its Effect on Prognosis.
    Medicina (Kaunas). 2026;62:2026.
    PubMed    
    Abstract available

  30. SAYLAM B, Temelli B, Nebioglu A, Efesoy O, et al
    Early Dynamic (18)F-FDG PET/CT SUVmax and Its Association with Pathological Stage and Tumor Grade in Bladder Cancer: A Prospective Exploratory Study.
    Medicina (Kaunas). 2026;62:2021.
    PubMed    
    Abstract available

  31. XIE F, Su M, Qiu W, Zhang M, et al
    Correction: Xie et al. Kaempferol Promotes Apoptosis in Human Bladder Cancer Cells by Inducing the Tumor Suppressor, PTEN. Int. J. Mol. Sci. 2013, 14, 21215-21226.
    Int J Mol Sci. 2026;27:8989.
    PubMed    
    Abstract available

  32. LIANG H, Li G, Zhang W, Wang W, et al
    pH-Responsive Erdafitinib Liposomes with FGFR3 Targeting for Intravesical Bladder Cancer Therapy.
    Int J Mol Sci. 2026;27:9014.
    PubMed    
    Abstract available

  33. CARAPITO A, Amaro F, Roque AC, Carvalho F, et al
    Urinary Metabolomics in Bladder Cancer: A Scoping Review of Current Evidence and Translation Implications.
    Int J Mol Sci. 2026;27:8983.
    PubMed    
    Abstract available

  34. DEMIRCILER E, Ozalp FR
    Opposing Natural Killer and Macrophage Associations Are Masked Within a CD16/IL-15/IL-15RA Composite Score in Metastatic Urothelial Carcinoma.
    Int J Mol Sci. 2026;27:8943.
    PubMed    
    Abstract available

  35. TAYLOR JA 3RD, Parikh RA, Chen Q, Woolbright BL, et al
    IV Vitamin C with Chemotherapy for Cisplatin-Ineligible Bladder Cancer Patients: A Forgotten Group.
    Antioxidants (Basel). 2026;15:1318.
    PubMed    
    Abstract available

  36. CHANG HH, Teng PC, Liu CH, Lin YL, et al
    A Programmed Cell Death Protein 1 Pathway-Derived Prognostic Transcriptomic Signature in Bladder Cancer: Development in TCGA-BLCA and Evaluation in Independent Cohorts.
    Curr Issues Mol Biol. 2026;48:1056.
    PubMed    
    Abstract available

  37. ZHANG X, Taoka R, Liu D, Hossain A, et al
    Targeting Glucose Metabolism in Bladder Cancer: Therapeutic Implications of 2-Deoxy-d-glucose.
    Curr Issues Mol Biol. 2026;48:993.
    PubMed    
    Abstract available

  38. DENG H, Sun R, He G, Tan Y, et al
    The SP4-NUPR1-SELM Axis Promotes Glycolytic Reprogramming and Stemness-Associated Phenotypes in Bladder Cancer.
    Cancers (Basel). 2026;18:3396.
    PubMed    
    Abstract available

  39. GHERASIM RD, Porav-Hodade D, Chibelean C, Voidazan S, et al
    Development and Internal Validation of the BRICS Score: A Preoperative Clinical and Hematological Model for Predicting High-Grade and Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2026;18:3282.
    PubMed    
    Abstract available

  40. YU P, Gao M, Feng X, Rong H, et al
    Gold Nanourchins Potentiate Intravesical Chemotherapy by Accelerating Drug Internalization within a Short Instillation Window.
    ACS Nano. 2026;20:28442-28456.
    PubMed    
    Abstract available

  41. CONTIERI R, Sormani F, Soloway M, Brausi M, et al
    Rethinking Recurrent LG Ta Bladder Cancer: A Multicenter Analysis of Oncological Safety and Treatment Burden in Patients Undergoing Active Surveillance or Office-Based Fulguration.
    Urol Pract. 2026 Oct 27:101097UPJ0000000000001111.
    PubMed    
    Abstract available

  42. GHASEMZADEH A, Pietzak EJ
    Tertiary Lymphoid Structures in Non-Muscle-Invasive Bladder Cancer: Quality over Quantity.
    Cancer Immunol Res. 2026 Oct 27:OF1-OF2. doi: 10.1158/2326-6066.CIR-26-1127.
    PubMed    
    Abstract available

  43. YU J, Fu Y
    MRI Radiomics Can Advance Phenotype-Based Characterization of Bladder Cancer Variants.
    J Med Imaging Radiat Oncol. 2026 Oct 27. doi: 10.1111/1754-9485.70215.
    PubMed    


  44. SANGKHATHAT S, Kanjanapradit K, Bejrananda T, Choochuen P, et al
    Prognostic Value of PD-L1 and Its Correlation with GATA3, CK5/6, and CK14 Expression in Muscle-Invasive Bladder Cancer.
    Asian Pac J Cancer Prev. 2026;27:3645-3653.
    PubMed    
    Abstract available

  45. WANG X, Jin L, Zhang Q, Li M, et al
    Novel nanotherapeutic strategy targeting mechanical tumor microenvironment in bladder cancer.
    J Nanobiotechnology. 2026;24:991.
    PubMed    
    Abstract available

  46. ZHENG M, Gao X, Liu J, Tan L, et al
    [Efficacy evaluation of extracellular vesicle drug delivery system in orthotopic intravesical perfusion for bladder cancer].
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2026;43:1068-1074.
    PubMed    
    Abstract available

  47. TYSON MD 2ND, Li R
    BCG-unresponsive non-muscle-invasive bladder cancer - Authors' reply.
    Lancet Oncol. 2026;27:e536.
    PubMed    


  48. SUN M, Zang D, Chen J
    BCG-unresponsive non-muscle-invasive bladder cancer.
    Lancet Oncol. 2026;27:e535.
    PubMed    


  49. SCILIPOTI P, Moschini M, Briganti A, Montorsi F, et al
    BCG-unresponsive non-muscle-invasive bladder cancer.
    Lancet Oncol. 2026;27:e534.
    PubMed    


  50. HUCK C, Zobouyan C, Pignot G, Marcq G, et al
    Postoperative radiotherapy after radical cystectomy for muscle-invasive bladder cancer: Patient selection, target delineation and contemporary evidence.
    Cancer Radiother. 2026;30.
    PubMed    
    Abstract available

  51. HUCK C, Pignot G, Masson-Lecomte A, Pasquier D, et al
    Quality of life after trimodal treatment for muscle-invasive bladder cancer.
    Cancer Radiother. 2026;30.
    PubMed    
    Abstract available

  52. ZHAO Y, Zhang S, Chen J
    ASO Author Reflections: From the Bedside to the Culture Dish: How Bladder Cancer Organoids Illuminate the Path Toward Precision Chemotherapy.
    Ann Surg Oncol. 2026 Oct 26. doi: 10.1245/s10434-026-20820.
    PubMed    


  53. ZHAO Y, Zhang S, Wang Y, Shen Z, et al
    Patient-Derived Organoids for Predicting Chemotherapy Response in Bladder Cancer: A Multicenter, Real-world Validation Study.
    Ann Surg Oncol. 2026 Oct 26. doi: 10.1245/s10434-026-20781.
    PubMed    
    Abstract available

  54. SCAVUZZO A, Castillejos-Molina RA, Bravo-Castro I, Jimenez-Rios MA, et al
    Patient Journey and Treatment Patterns of Non-Muscle-Invasive Bladder Cancer in Mexico.
    Curr Oncol. 2026;33:597.
    PubMed    
    Abstract available

  55. POWLES T, Grande E, Simone G, Gomez de Liano A, et al
    Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.
    N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2608323.
    PubMed    
    Abstract available

  56. HAIYA F, Qianqian L, Yangjun L, Hui W, et al
    Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis.
    J Cancer Res Clin Oncol. 2026;152:203.
    PubMed    
    Abstract available

  57. LENG X, Lu W, Zhou R, Wang C, et al
    Targeting MRPL37 disrupts the pro-tumorigenic mitochondrial cascade in bladder cancer: from LRPPRC deficiency to ROS/AKT axis inhibition.
    Biol Direct. 2026;21:215.
    PubMed    
    Abstract available

  58. JIN X, Xu Y, Ling K, Li H, et al
    Elevated GANAB fuels PD-1/PD-L1 checkpoint-mediated immune escape by maintaining PD-L1 stability in bladder cancer.
    Cell Signal. 2026;150:112937.
    PubMed    
    Abstract available

  59. WILLIAMS B, Sandoughdaran S, Chick J, Dunlop A, et al
    Feasibility of reduced PTV margins in magnetic resonance image-guided online adaptive radiotherapy for bladder cancer: a personalised approach.
    Clin Transl Radiat Oncol. 2026;62:101321.
    PubMed    
    Abstract available

  60. NECCHI A, Mercinelli C, Maiorano BA, Piacentini M, et al
    Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.
    Nat Med. 2026 Oct 24. doi: 10.1038/s41591-026-04740.
    PubMed    
    Abstract available

  61. ZHENG C, Ren X, Qian C, Lei Z, et al
    Multi-omics profiling of FFPE tissues identifies serine synthesis and impaired creatine metabolism as metabolic hallmarks of high-grade bladder cancer.
    Urol Oncol. 2026 Oct 24:S1078-1439(26)00749.
    PubMed    
    Abstract available

  62. MORIYAMA S, Shinohara M, Ogawa K, Inui K, et al
    Single-Port Robot-Assisted Radical Cystectomy Using Combined Umbilical and Perineal Access: Initial Clinical Experience With Exploratory Comparison of Multiport Surgery.
    Int J Med Robot. 2026;22:e70240.
    PubMed    
    Abstract available

  63. SASAKI Y, Fukuta K, Kadoriku F, Hori K, et al
    Real-world implementation of robot-assisted radical cystectomy at four Japanese institutions: perioperative outcomes, major complications, and mortality.
    J Robot Surg. 2026;20:1129.
    PubMed    
    Abstract available

  64. ANDRE C, Tournier L, Fardeau E, Fiore A, et al
    Type A acute aortic dissection associated with 5-fluorouracil: A rare but serious vascular toxicity.
    Bull Cancer. 2026;113:1303-1305.
    PubMed    
    Abstract available

  65. ZEMANKOVA A, Melichar B, Eid M, Poprach A, et al
    Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.
    Future Oncol. 2026;22:2709-2715.
    PubMed    
    Abstract available

  66. YAJIMA S, Okumura G, Yoshida S, Chen W, et al
    Time-varying prognostic value of circulating tumor DNA in urothelial carcinoma: A systematic review and reconstructed patient-data meta-analysis.
    Crit Rev Oncol Hematol. 2026;227:105560.
    PubMed    
    Abstract available

  67. ZHANG T, Zhang H
    Urinary biomarkers for cancer diagnosis and surveillance: From analytical promise to clinical utility.
    Crit Rev Oncol Hematol. 2026;227:105519.
    PubMed    
    Abstract available

  68. DANESHMAND S, Wuyts K, Meulder M, Vereyken L, et al
    Tissue Penetration of Gemcitabine and Gemcitabine Phosphate Metabolites Following Gemcitabine Intravesical System Administration Versus Standard Intravesical Instillation in a Preclinical Minipig Model.
    Eur Urol Focus. 2026;12:888-892.
    PubMed    
    Abstract available

  69. ZHU S, Kohler L, Ergun B, Meierhofer D, et al
    An MMP-14/STAT3 feedback loop upregulates PD-L1 to drive immunosuppression and tumorigenesis in bladder cancer.
    iScience. 2026;29:118071.
    PubMed    
    Abstract available

  70. ZHANG J, Zhou H, Li J, Liu T, et al
    Exploring the role of RPS2 in muscle-invasive bladder cancer progression and resistance: A nanovesicle-based therapeutic approach.
    J Pharm Anal. 2026;16:101628.
    PubMed    
    Abstract available

  71. HUANG LH, Tung MC, Weng WC, Hsu CY, et al
    Neoadjuvant Nivolumab-Ipilimumab versus Platinum-Based Chemotherapy in Muscle-Invasive Bladder Cancer: A Single-Institution, Propensity-Weighted Cohort Study.
    Cancer Manag Res. 2026;18:642002.
    PubMed    
    Abstract available

  72. ZHANG C, Zhang Z, Bi J
    Therapy-induced methionine competition in bladder cancer: MAT2A-SAM axis remodeling as a metabolic immune checkpoint.
    Front Immunol. 2026;17:1965813.
    PubMed    
    Abstract available

  73. CHEN C, Xie B, Chen C, Gu P, et al
    Defining safe bladder preservation in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: beyond complete response.
    Front Immunol. 2026;17:1983996.
    PubMed    
    Abstract available

  74. LIU J, Guo Z, Guo J, Xing S, et al
    Evidence gaps and route-dependent development requirements for CAR cellular therapy in urothelial carcinoma: a systematic evidence map and public-data analysis.
    Front Immunol. 2026;17:1941701.
    PubMed    
    Abstract available

  75. ATHANS S, Young M, Yu H, Doshi B, et al
    Tumor SETDB1 expression predicts worse overall survival for bladder cancer patients.
    bioRxiv [Preprint]. 2026 Oct 27:2026.10.23.761403.
    PubMed    
    Abstract available

  76. MAENG S, Kim MJ, Kim M, Tae JH, et al
    Ultrasound-triggered release of gemcitabine-loaded liposomes enhances intravesical therapy for bladder cancer.
    Investig Clin Urol. 2026;67:587-597.
    PubMed    
    Abstract available

  77. NOMURA N, Sekino Y, Shigematsu Y, Kobayashi G, et al
    KIF23 is associated with a poor prognosis, basal subtypes and immunotherapy response in urothelial carcinoma.
    Investig Clin Urol. 2026;67:530-542.
    PubMed    
    Abstract available

  78. MAO W, Huang X, Wang L, Zhang Z, et al
    Retraction Note: Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression.
    J Exp Clin Cancer Res. 2026;45:229.
    PubMed    


  79. LI K, Tan YK, Li ZB, Xiang R, et al
    JQ1 targeting BRD4 enhances cisplatin-induced pyroptosis via LDHA-mediated ROS release to potentially overcome chemoresistance in bladder cancer.
    Biochim Biophys Acta Mol Basis Dis. 2026 Nov 5:168510.
    PubMed    
    Abstract available

  80. LAWRENTSCHUK N, Carll J, Li P, Henderson K, et al
    Managing complications of ileal conduits in primary care.
    Aust J Gen Pract. 2026;55:774-778.
    PubMed    
    Abstract available

  81. MIYAJIMA K, Miszczyk M, Rabil MJ, Lubbersmeyer F, et al
    Intravesical BCG-induced granulomatous prostatitis mimicking prostate cancer in patients with non-muscle invasive bladder cancer: a systematic review.
    World J Urol. 2026;44:787.
    PubMed    
    Abstract available

  82. HOU L, Xiao Y, Xiao K, Tao X, et al
    Detection of Stage-Dependent Collagen Remodeling at the Bladder Cancer Invasive Front by Label-Free Multiphoton Imaging.
    J Biophotonics. 2026;19:e70387.
    PubMed    
    Abstract available

  83. NAIM N, Saad A, Mohamad N, Kattan J, et al
    Optimal timing of adjuvant immunotherapy after radical cystectomy in muscle-invasive bladder cancer: from calendar-based to MRD-guided decision making.
    Front Oncol. 2026;16:1933232.
    PubMed    
    Abstract available

  84. DONG X, Zhang J, Liu M, Sun R, et al
    Advances in Novel Protein Acylation in Urothelial Carcinoma: Research Progress and Biomarker Potential.
    Oncol Res. 2026;34:13.
    PubMed    
    Abstract available

  85. SONG DM, Lu H, Shu YC, Xu JJ, et al
    Overexpression of TUBA1A suppresses bladder cancer progression with potential modulation of autophagic activity and macrophage polarization.
    Front Immunol. 2026;17:1921855.
    PubMed    
    Abstract available

  86. TUNCEKIN A, Aktas Y, Turk H, Tongal A, et al
    Diagnostic stage discordance and survival in T2 bladder cancer: rethinking the clinical behavior of progressive disease.
    BMC Urol. 2026;26:278.
    PubMed    
    Abstract available

  87. TOBE T, Miyata Y, Nakamura Y, Hara T, et al
    Exploring vertical genomic heterogeneity and chemotherapy response using targeted genomic sequencing in muscle-invasive bladder cancer.
    BMC Urol. 2026;26:276.
    PubMed    
    Abstract available

  88. LI G, Tan C, Wei J, Chen S, et al
    Prognostic value of the inflammatory prognostic index for postoperative recurrence in non-muscle-invasive bladder cancer.
    BMC Urol. 2026;26:275.
    PubMed    
    Abstract available

  89. GUAN H, Liu X, Hong T, Li H, et al
    Integrative Multi-Omics Analysis with Interpretable Machine Learning Prioritizes Candidate Biomarkers for Bladder Cancer.
    Curr Gene Ther. 2026 Oct 27. doi: 10.2174/0115665232538656261006070001.
    PubMed    
    Abstract available

  90. SIVA J, McKenney JK, Guzman T, Diaz GM, et al
    Clinical Outcomes and Malignant Potential of Urothelial Atypia Without Previous Bladder Cancer.
    Eur Urol Focus. 2026 Nov 4:S2405-4569(26)00261-0. doi: 10.1016/j.euf.2026.
    PubMed    
    Abstract available

  91. HUANG S, Xue Z, Kang N, Ma B, et al
    Postresection Urinary Tumor DNA Refines Residual Disease Assessment and Recurrence Risk Stratification in Non-Muscle-Invasive Bladder Cancer.
    JCO Precis Oncol. 2026;10:e2600676.
    PubMed    
    Abstract available

  92. GUERRERO-RAMOS F, Fernandez Gomez JM, Aparicio TF, Lopez-Beltran A, et al
    Evaluation of large language models for guideline-based clinical questions in muscle-invasive and non-muscle-invasive bladder cancer and upper tract urothelial carcinoma: a multidisciplinary Delphi study.
    J Comp Eff Res. 2026 Nov 4:e260079. doi: 10.57264/cer-2026-0079.
    PubMed    
    Abstract available

  93. ZHANG G, Mu J, Shi X, Bao Z, et al
    Preliminary development and internal evaluation of a plasma SOX1 methylation-based model bladder cancer detection.
    Open Life Sci. 2026;21:20251396.
    PubMed    
    Abstract available

  94. NIELSEN NK, Jensen JB
    Reply to Xin Li and Yapeng Xing's Letter to the Editor re: Nielsen N.K, Hjort P.B, Hansen E.B, et al. Substaging and stratified treatment of T1 bladder cancer - a nationwide register-based study. Eur Urol Open Sci 2026;90:92-100.
    Eur Urol Open Sci. 2026;93:65-66.
    PubMed    


  95. LI D, Sun X, Yu T
    From epidemiology to molecular pathology: current research status and future prospects on the role of toxic metal exposure in the development and progression of bladder cancer.
    Front Cell Dev Biol. 2026;14:1930640.
    PubMed    
    Abstract available

  96. QIN B, Liang H, Kuang T, Wei C, et al
    Anti-bladder cancer effects of nuciferine, a bioactive compound extracted from Nelumbo nucifera leaves.
    Front Nutr. 2026;13:1881388.
    PubMed    
    Abstract available

  97. Y PATEL M, Wang X, Castelino R, Milloy N, et al
    Evolution of treatment distribution and patient characteristics of muscle invasive bladder cancer patients: results from two multi-national real-world surveys.
    BMC Urol. 2026;26:274.
    PubMed    
    Abstract available

  98. ABE S, Tsutsumi N, Hoshiyama A, Kamiyama Y, et al
    [A CASE OF BCG-ASSOCIATED INTERSTITIAL PNEUMONIA WITH Mycobacterium bovis BACTEREMIA SUCCESSFULLY TREATED WITH CORTICOSTEROIDS ALONE].
    Hinyokika Kiyo. 2026;72:325-329.
    PubMed    
    Abstract available

  99. HAYASHI Y, Iida K, Narita K, Itami Y, et al
    [A CASE OF POLYMYALGIA RHEUMATICA (PMR)-LIKE irAE DEVELOPING DURING NIVOLUMAB ADMINISTRATION AFTER SURGERY FOR MUSCLE-INVASIVE BLADDER CANCER : A CASE REPORT].
    Hinyokika Kiyo. 2026;72:319-323.
    PubMed    
    Abstract available

  100. HUANG S, Li Y, Shi Y, Zhang F, et al
    piR-34379 inhibits bladder cancer progression and reverses cisplatin resistance by downregulating ACAT2-mediated PKM2 lactylation.
    Cell Signal. 2026 Nov 3:112978. doi: 10.1016/j.cellsig.2026.112978.
    PubMed    
    Abstract available

  101. LIU Y, Bian Z, Hu J, Xie Y, et al
    Integrative multi-omics analysis reveals a GALNT6/Smad2/CDC7 axis promoting cisplatin resistance through enhanced DNA damage repair in bladder cancer.
    Funct Integr Genomics. 2026;26:315.
    PubMed    
    Abstract available

  102. UNAL B, Imanli G, Ilki FY, Bedir S, et al
    Short communication: Urinary schistosomiasis mimicking a bladder tumour in a Somali student diagnosed in Turkiye.
    J Helminthol. 2026;100:e156.
    PubMed    
    Abstract available

  103. WOJCIK EM
    Beyond morphology: Toward integrated risk assessment in urinary cytology.
    Cancer Cytopathol. 2026;134:e70164.
    PubMed    
    Abstract available

  104. CONTIERI R, de Angelis M, Scilipoti P, Pellegrino F, et al
    When, where, and in whom does recurrence occur after radical cystectomy for pathologically confirmed non-muscle-invasive bladder cancer? Implications for risk-adapted surveillance.
    World J Urol. 2026;44:780.
    PubMed    
    Abstract available

  105. WOOD JL, Lum B, Ghosh S, Staudacher AH, et al
    Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer.
    Mol Pharm. 2026;23:5879-5890.
    PubMed    
    Abstract available

  106. ENDERLIN D, Gloor M, Bieri U, Mazumdar A, et al
    Prognostic Impact of Nectin4 and IRF6 Expression in Patients Undergoing Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Cancer Diagn Progn. 2026;6:947-960.
    PubMed    
    Abstract available

  107. CHENG L, van Leenders GJLH
    International Society of Urological Pathology (ISUP) Multidisciplinary Expert Consultation on Treatment Effects in Prostate and Bladder Cancer: Toward Standardized Pathologic Evaluation in the Era of Precision Medicine.
    Am J Surg Pathol. 2026 Nov 2. doi: 10.1097/PAS.0000000000002646.
    PubMed    


  108. JACOBI JJ, Xu D, Wieczorek K, Wang L, et al
    Single-cell profiling uncovers a rare mesenchymal-like urothelial state associated with sarcomatoid bladder cancer.
    Cell Death Dis. 2026;17:927.
    PubMed    
    Abstract available

  109. WANG Y, Wu X, Shu C, Bao T, et al
    SLC9A3R1 Promotes Bladder Cancer Progression Through Regulation of Malignant Phenotypes: Integrated Bioinformatics Analysis and Experimental Validation.
    Cancer Invest. 2026 Nov 1:1-16. doi: 10.1080/07357907.2026.2757870.
    PubMed    
    Abstract available

  110. CHEE CS, Ha ID, Lee Y, Lee H, et al
    Nonparametric maximum likelihood estimation for competing risks frailty models.
    Lifetime Data Anal. 2026;32:57.
    PubMed    
    Abstract available

  111. LOTAN Y, Korman H, Gadzinski A, Cohen J, et al
    Postinduction Urine Tumor DNA Is Predictive for Response to Maintenance Intravesical Therapy in Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2026 Oct 31:S2588-9311(26)00286.
    PubMed    
    Abstract available

  112. MA W, Liu Y, Tang L, Ouyang S, et al
    Serial urinary NGAL and CK20 for dynamic cardiovascular risk stratification in non-muscle-invasive bladder cancer: a retrospective clinical cohort study.
    Front Cardiovasc Med. 2026;13:1949457.
    PubMed    
    Abstract available

  113. ROUDSARI H, Dhaliwal G, Jagannath AD, Baik AH, et al
    Old disease, new twist.
    J Hosp Med. 2026;21:1305-1309.
    PubMed    
    Abstract available

  114. ZHANG HP, Fu F, Fan XQ, Li ZY, et al
    Application Study of Clinical Features Combined With Ultrasound-based Radiomics Nomogram For Grading Diagnosis of Bladder Urothelial Carcinoma.
    Acad Radiol. 2026;33:5208-5217.
    PubMed    
    Abstract available

  115. NGUYEN JK, Toscano MP, Li J, Williamson SR, et al
    Hybrid grading systems improve progression risk stratification in non-invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression.
    Histopathology. 2026;89:1064-1082.
    PubMed    
    Abstract available

  116. OZGUR G, Genc YE, Ozdemiroglu C, Bektas BM, et al
    Risk factors for obturator nerve reflex during bipolar transurethral resection of lateral bladder wall tumors.
    Actas Urol Esp (Engl Ed). 2026;50:502007.
    PubMed    
    Abstract available

  117. HOSHINA H, Sugihara T, Kurokawa M, Takaoka EI, et al
    Impact of the modified Frailty Index-5 on treatment selection and prognosis in octogenarians with bladder cancer eligible for radical cystectomy: a single-center, retrospective study.
    BMC Urol. 2026;26:290.
    PubMed    
    Abstract available

  118. MI Z, Wu J, Tian X, Wang G, et al
    SDC2 promotes gemcitabine resistance of bladder cancer via activation of the EGFR-ERK-C-MYC axis mediated epithelial-mesenchymal transition.
    Cell Cycle. 2026;25:1-20.
    PubMed    
    Abstract available

  119. SUARTZ CV, Fernandes LR, Alves CNN, Casini JVF, et al
    Perioperative immunotherapy in muscle-invasive bladder cancer: a narrative review of neoadjuvant, adjuvant, and antibody-drug conjugate-based strategies.
    Immunotherapy. 2026 Nov 12:1-14. doi: 10.1080/1750743X.2026.2756124.
    PubMed    
    Abstract available

  120. STARRETT JH, Bensen DC, Swanson RV, Hudkins RL, et al
    FGFR3 Selectivity in Drug Discovery: Biological Rationale, Design Strategies, and Therapeutic Potential.
    J Med Chem. 2026;69:24975-24995.
    PubMed    
    Abstract available

  121. FAZAA N, Gofer M, Eigner E, Atallah M, et al
    When should bladder cancer prompt evaluation for Lynch syndrome? An evidence-informed clinical framework.
    Front Oncol. 2026;16:2015634.
    PubMed    
    Abstract available

  122. ROCCO B, Totaro A, Assumma S, Panio E, et al
    ICG-guided intracorporeal intestinal diversion with the Hugo RAS system following radical cystectomy: technological background and case report.
    Can J Urol. 2026;33:1327-1332.
    PubMed    
    Abstract available

  123. GIUDICE FD, Corvino R, Santarelli V, Razeto E, et al
    Artificial intelligence software CystoSmart for papillary or flat lesions during bladder endoscopy: a prospective observational pilot study protocol.
    Can J Urol. 2026;33:1251-1259.
    PubMed    
    Abstract available

  124. ZHOU H, Zhao Y, Li J, Qi Y, et al
    A multi-omics analysis and clinical relevance of regulated cell death in bladder cancer.
    Can J Urol. 2026;33:1227-1250.
    PubMed    
    Abstract available

  125. SAKALIS V, Chatzigriva E, Pang KH, Rai BP, et al
    The role of artificial intelligence in urological malignancies: an overview of systematic reviews.
    Can J Urol. 2026;33:1061-1087.
    PubMed    
    Abstract available

  126. HUANG Y, Li C, Wang J, Wang W, et al
    A case report of rare primary extraosseous Ewing sarcoma of the bladder is presented, with confirmation by pathological, immunohistochemical, and molecular analyses.
    J Med Case Rep. 2026;20:723.
    PubMed    
    Abstract available

  127. WANG W, Wu W, Zhang H, Liu X, et al
    Engineering a dual-function attenuated Bacillus Calmette-Guerin (BCG) co-expressing interleukin-12 (IL-12) and granulysin (GLS) for enhanced cytotoxicity and immune remodeling in bladder cancer.
    Int J Biol Macromol. 2026 Nov 11:155235. doi: 10.1016/j.ijbiomac.2026.155235.
    PubMed    
    Abstract available

  128. YANG H, Bao X, Lu Q, Hou X, et al
    Bladder Cancer Burden 1990-2021 Age, Sex, and Regional Disparities in <55 and 55+ Populations.
    Cancer Control. 2026;33:10732748261506958.
    PubMed    
    Abstract available

  129. HUANG CS, Yu CP, Yu DS, Wu YS, et al
    Extracellular vesicles as integrative hubs of drug resistance in bladder cancer.
    Cancer Drug Resist. 2026;9:37.
    PubMed    
    Abstract available

  130. QIN S, Yu X, Zuo S, He X, et al
    Bladder cancer immune microenvironment: immune-cell distribution, disease associations, treatment remodeling, and baseline immune features associated with treatment response and prognosis.
    Front Oncol. 2026;16:1985263.
    PubMed    
    Abstract available

  131. YANG M, Chen H, Mao H, Ye X, et al
    A DNA Nanoplatform with Rolling Circle-DNAzyme Feedback Programming for Autonomous Exponential Amplification Enables Multiplexed Orthogonal miRNA Profiling toward Precise Diagnosis of Bladder Cancer.
    Anal Chem. 2026;98:31317-31327.
    PubMed    
    Abstract available

  132. LLOYD L
    Temporal trajectories - the evolution of lethal metastatic bladder cancer subtypes.
    Nat Rev Urol. 2026 Nov 10. doi: 10.1038/s41585-026-01217.
    PubMed    


  133. HUDSON C, Nguyen M, Ostergar A, Tyson M, et al
    Radical Cystectomy: Perioperative Complications.
    Urol Clin North Am. 2027;54:49-61.
    PubMed    
    Abstract available

  134. ROADMAN DF, Shah PV, Janakiraman S, Koehne EL, et al
    Complications of Transurethral Resection of Bladder Tumors: A Contemporary Review.
    Urol Clin North Am. 2027;54:25-35.
    PubMed    
    Abstract available

  135. LEE J, Kang ES, Park HS, Kim K, et al
    Elevated Risk of Bladder Cancer Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease in Elderly Korean Men: A Nationwide Cohort Study.
    J Korean Med Sci. 2026;41:e274.
    PubMed    
    Abstract available

  136. LU J, Jie K, Liu C, Lai J, et al
    A patient-derived bladder cancer organoid and xenograft platform for personalized drug response prediction and salvage therapeutics screening.
    Chin J Cancer Res. 2026;38:661-678.
    PubMed    
    Abstract available

  137. QU L, Qu Z, Ye X, Yuan G, et al
    Multiparametric MRI radiomics combined with clinical-radiologic features improves preoperative prediction of muscle invasion in bladder cancer.
    Front Oncol. 2026;16:1949830.
    PubMed    
    Abstract available

  138. KIM YJ, Kim KH, Lee KW, Kim JH, et al
    Feasibility and mid-term outcomes of simultaneous robot-assisted laparoscopic radical prostatectomy and transurethral resection of bladder tumor: a single-center case series.
    BMC Urol. 2026;26:285.
    PubMed    
    Abstract available

  139. LIU Z, Hu Y, Lyu J, Deng L, et al
    Biparametric MRI with deep learning for the preoperative prediction of muscle invasion in patients with bladder cancer: a multicenter study.
    Insights Imaging. 2026;17:289.
    PubMed    
    Abstract available

  140. WU X, Zhao Z, Ouyang S, Hao X, et al
    GlycoStamp-seq: Single-cell nascent sialoglycometabolomics captures sialylation dynamics in immune cells of an oxaliplatin-treated bladder cancer mouse model.
    Nat Commun. 2026;17:11542.
    PubMed    
    Abstract available

  141. FUKATA S, Ichimura N, Suzuki Y, Kohno S, et al
    Component-specific institutional learning curve of intracorporeal urinary diversion during robot-assisted radical cystectomy: a risk-adjusted cumulative sum analysis.
    J Robot Surg. 2026;20:1186.
    PubMed    
    Abstract available

  142. GONCALVES JM, de Arruda Camargo GC, de Oliveira G, Caria PHF, et al
    Clinical and translational profiling of oncotherad (MRB-CFI-1) nanoimmunotherapy identifies HER-2/SERBP1-associated recurrence and HABP4/IFN-gamma-associated disease control in pT1 non-muscle-invasive bladder cancer after BCG failure.
    J Cancer Res Clin Oncol. 2026;152:219.
    PubMed    
    Abstract available

  143. NOWAKOWSKI D, Mackowiak W, Majer K, Mirkiewicz W, et al
    Prehabilitation in oncology patients, with particular emphasis on bladder cancer surgery.
    Support Care Cancer. 2026;34:1210.
    PubMed    
    Abstract available

  144. LIDINGTON E, Schmeising-Barnes N, Goff M, Carter A, et al
    Acceptability of at-home urine self-testing for bladder health problems: a qualitative study.
    BMC Public Health. 2026;26:3259.
    PubMed    
    Abstract available

  145. LU W, Fu P, Li C, Lou K, et al
    Stem Cell-Derived Extracellular Vesicles in Bladder Cancer: Diagnostic Potential and Therapeutic Challenges.
    Int J Nanomedicine. 2026;21:631382.
    PubMed    
    Abstract available

  146. HOSSEINI SY, Safarinejad MR, Amini E, Hooshyar H, et al
    Retraction notice to "Opium Consumption and Risk of Bladder Cancer: A Case-Control Analysis" Urologic Oncology: Seminars and Original Investigations 28 (2010) 610-616.
    Urol Oncol. 2026 Nov 7:S1078-1439(26)00753-2. doi: 10.1016/j.urolonc.2026.
    PubMed    


  147. ZHANG M, Chen C, Zhao Q, Zeng X, et al
    Enhanced image quality and interpretation efficiency of voxelwise-computed diffusion-weighted imaging for bladder cancer VI-RADS assessment.
    Abdom Radiol (NY). 2026 Nov 7. doi: 10.1007/s00261-026-05860.
    PubMed    
    Abstract available

  148. YUANJIANG Q, Liming Y
    Epigenetic reprogramming in Urothelial bladder cancer: mechanisms, biomarkers, and therapeutic opportunities.
    Epigenetics. 2026;21:2753250.
    PubMed    
    Abstract available

  149. AZAD F, Kevu E, Aragon-Ching JB
    Navigating the current and future perioperative treatment landscape of muscle-invasive bladder cancer (MIBC).
    Transl Cancer Res. 2026;15:786.
    PubMed    
    Abstract available

  150. FUJIWARA M, Tanaka H, Hirahara D, Saho T, et al
    Machine learning models to predict pathological complete response after chemoradiotherapy in muscle-invasive bladder cancer: toward optimized indications for bladder preservation.
    Clin Transl Radiat Oncol. 2026;62:101320.
    PubMed    
    Abstract available

  151. IMASUEN P, Bal DS, Chung D, Nayak J, et al
    Rural-urban disparities in high-risk non-muscle-invasive bladder cancer: lessons from the Canadian Bladder Cancer Information System.
    Transl Androl Urol. 2026;15:397.
    PubMed    


  152. LUO P, Xie J, Kang R, Deng W, et al
    Development and external validation of a psychological stress-related gene signature for overall survival prediction in bladder cancer.
    Transl Androl Urol. 2026;15:368.
    PubMed    
    Abstract available

  153. JANG A, Mitchell B, Brown JR, Koshkin VS, et al
    Fibroblast growth factor receptor inhibitors for non-muscle-invasive bladder cancer: THOR-2 and beyond.
    Transl Androl Urol. 2026;15:391.
    PubMed    


  154. LI Z, Zhang Y, Li X, Li H, et al
    A bibliometric and knowledge-mapping analysis of bladder cancer organoid research based on Web of Science, Scopus, and PubMed.
    Transl Androl Urol. 2026;15:382.
    PubMed    
    Abstract available

  155. DOSHI B, Gomez EC, Foster BA, Wang J, et al
    Sex Differences in DNA Methylation and Gene Expression Reveal Distinct Molecular Programs in Muscle-Invasive Bladder Cancer.
    bioRxiv [Preprint]. 2026 Oct 23:2026.10.21.760777.
    PubMed    
    Abstract available

  156. JOHN B, Casuscelli J, Buchner A, Brinkmann I, et al
    Impact of Preoperative Sarcopenia on Survival and Perioperative Outcomes After Radical Cystectomy for Bladder Cancer.
    Clin Genitourin Cancer. 2026 Oct 13:102695. doi: 10.1016/j.clgc.2026.102695.
    PubMed    
    Abstract available

  157. MARI A, Giudici S, Grobet-Jeandin E, Claps F, et al
    Sex-disaggregated Outcomes and Safety Reporting in Perioperative Systemic Therapy for Muscle-invasive Bladder Cancer: A Systematic Review.
    Eur Urol Oncol. 2026 Nov 6:S2588-9311(26)00251-8. doi: 10.1016/j.euo.2026.
    PubMed    
    Abstract available

  158. HU J, Liu Y, Chen M, Ou J, et al
    Spatiotemporal dynamic evolution of the tumor microenvironment during neoadjuvant immunotherapy for bladder cancer.
    Cell Rep Med. 2026 Nov 6:103140. doi: 10.1016/j.xcrm.2026.103140.
    PubMed    
    Abstract available

  159. LITT HK, Sahni A, Mo G, Patel K, et al
    Real-world adoption of circulating tumor DNA testing and adjuvant treatment decisions after radical cystectomy for muscle-invasive bladder cancer.
    ESMO Open. 2026;11:108619.
    PubMed    
    Abstract available

  160. ZHANG H, Yang Y, Liu Z, Zhao F, et al
    RBM15 Contributes to Bladder Carcinoma Progression via m6A-dependent Stabilization of IFI6 mRNA.
    Appl Biochem Biotechnol. 2026;198:10969-10982.
    PubMed    
    Abstract available

  161. XU K, Kong L, Ye K, Bao X, et al
    Modification-Selective Inhibition of Succinate Dehydrogenase a Enables Tumor-Restricted Mitochondrial Modulation.
    Adv Sci (Weinh). 2026;13:e77046.
    PubMed    
    Abstract available

  162. CALAGUA C, Bhardwaj S, Cholan VO, Hojabri M, et al
    Clinical impact of second opinion consultation in bladder biopsies and transurethral resection of bladder tumors.
    Hum Pathol. 2026;177:106210.
    PubMed    
    Abstract available

  163. LI W, Wu R, Fang P, Huang T, et al
    Decoding hypoxia-driven microenvironment remodeling in bladder cancer reveals TPST1 as a key driver of metastasis.
    World J Surg Oncol. 2026;24:439.
    PubMed    
    Abstract available

  164. YANG M, Li R, Huang Z, Shao W, et al
    Tetrahydrocurcumin suppresses bladder cancer progression by modulating SPP1-associated M2 macrophage-tumor interaction.
    Mol Biomed. 2026;7:252.
    PubMed    
    Abstract available

  165. IBRAHIM Y, Rajain S, Abu-Ghanem Y, Ribeiro L, et al
    Outcomes of robot-assisted cystectomy and intracorporeal ileal conduit diversion in radiotherapy-exposed patients: propensity-score matched analysis.
    World J Urol. 2026;44:827.
    PubMed    
    Abstract available

  166. XU H, Bai Y
    Re: Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.
    Urol Oncol. 2026 Nov 20:S1078-1439(26)00775.
    PubMed    


  167. LEE SY, Jang S, Lee D, Jo D, et al
    Prognostic Significance of AI-Quantified Central Tumor-Infiltrating Lymphocytes in Bladder Cancer.
    Lab Invest. 2026 Nov 20:106183. doi: 10.1016/j.labinv.2026.106183.
    PubMed    
    Abstract available

  168. GAO M, Tian J, Guo H, Xu H, et al
    A urea-powered platelet micromotor initiates self-amplifying ECM remodeling to potentiate BCG immunotherapy in bladder cancer.
    Biomaterials. 2026;339:124784.
    PubMed    
    Abstract available

  169. SILIPIGNI S, Arillotta GM, Maccarrone E, Racchiusa S, et al
    Spectral CT for Assessing Local Tumor Invasion in Bladder Cancer.
    Radiol Imaging Cancer. 2026;8:e260451.
    PubMed    



  170. Cell-free RNA in Urine May Detect Bladder Cancer and Distinguish Response.
    Cancer Discov. 2026 Nov 20:OF1. doi: 10.1158/2159-8290.CD-RW2026.
    PubMed    


  171. LI Z, Zhang TB, Jia DH, Sun WQ, et al
    [Retracted] Genipin inhibits the growth of human bladder cancer cells via inactivation of PI3K/Akt signaling.
    Oncol Lett. 2026;33:14.
    PubMed    
    Abstract available


  172. Statement of Retraction: Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer.
    Bioengineered. 2026;17:2749381.
    PubMed    


  173. CIN H, Gulmez H, Turan T
    Impact of pioglitazone use on clinicopathological features and aggressiveness of bladder cancer: a retrospective cohort study.
    BMC Urol. 2026;26:304.
    PubMed    


  174. AZZOUZI ME, HafidiAlaoui C, Ahanidi HE, Imane C, et al
    TP53 Sequence Variant Profiling in Moroccan Patients with Non-Metastatic Bladder Cancer: Analysis of Exons 4-9.
    Fr J Urol. 2026 Nov 19:103290. doi: 10.1016/j.fjurol.2026.103290.
    PubMed    
    Abstract available

  175. WU Y, Xu Z, Yin L, Wang R, et al
    Lactylation-driven NOP2 stabilization suppresses ferroptosis to promote cisplatin resistance via enhancing m5C-Dependent GLS1 mRNA stability in bladder cancer.
    Cancer Lett. 2026 Nov 19:218989. doi: 10.1016/j.canlet.2026.218989.
    PubMed    
    Abstract available

  176. GAYE O, Diallo K, Fall CB, Comperat E, et al
    Molecular mechanisms of Schistosoma haematobium-associated bladder carcinogenesis and urinary biomarkers for early diagnosis: A review.
    PLoS Negl Trop Dis. 2026;20:e0014868.
    PubMed    
    Abstract available

  177. LU P, Zhou L
    Cancer-associated fibroblasts and extracellular matrix remodeling driving drug resistance and immune evasion in bladder cancer: research progress.
    Front Immunol. 2026;17:1941274.
    PubMed    
    Abstract available

  178. DAMA M, Ahmadzada J, Efiloglu O, Bozkurt YE, et al
    The prognostic impact of variant histology timing in bladder cancer: a comparative analysis of primary and secondary detection.
    BMC Urol. 2026;26:300.
    PubMed    
    Abstract available

  179. MATSUKAWA A, Mori K, Yanagisawa T, Miyajima K, et al
    Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Network Meta-analysis.
    Target Oncol. 2026 Nov 18. doi: 10.1007/s11523-026-01270.
    PubMed    
    Abstract available

  180. KOYAMA Y, Takanashi M
    Targeting neutral sphingomyelinase enhances NK cell-mediated immunity via the CXCL10-CXCR3 axis in murine bladder cancer cells.
    Cancer Immunol Immunother. 2026;75:288.
    PubMed    
    Abstract available

  181. ROUMIGUIE M, Marcq G, Bajeot AS, Allory Y, et al
    French AFU Cancer Committee Guidelines - Update 2026-2028: Muscle-invasive bladder tumors (MIBC).
    Fr J Urol. 2026;36:103192.
    PubMed    
    Abstract available

  182. ROUMIGUIE M, Pradere B, Bajeot AS, Leon P, et al
    French AFU Cancer Committee Guidelines - Update 2026-2028: Non-muscle-invasive bladder tumors (NMIBC).
    Fr J Urol. 2026;36:103182.
    PubMed    
    Abstract available

  183. CRONIN C, Wallace BK, Gumma ME, Weitzner AS, et al
    Is all gross hematuria high risk? Age-stratified outcomes after anticoagulation initiation using a large claims database.
    Urol Oncol. 2026;44:969-976.
    PubMed    
    Abstract available

  184. GALSKY MD
    Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer. Reply.
    N Engl J Med. 2026;395:2074-2075.
    PubMed    


  185. KIKILI CI, Kemik F, Tural D
    Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer.
    N Engl J Med. 2026;395:2073-2074.
    PubMed    


  186. TAKEMURA K, Miura Y, Kitano S
    Enfortumab Vedotin and Pembrolizumab for Cisplatin-Eligible Bladder Cancer.
    N Engl J Med. 2026;395:2073.
    PubMed    


  187. ISKENDER B, Izgi K
    Evaluation of a KLH-conjugated uroplakin 3A-derived peptide formulation in an OH-BBN bladder cancer model.
    Med Oncol. 2026;43:388.
    PubMed    
    Abstract available

  188. CARVALHO FLF, Lee J, Kalavros N, Zhou Y, et al
    Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer.
    Cell Press Blue. 2026;1:100100.
    PubMed    
    Abstract available

  189. KUMARI R, Bhushan A, Kaur J, Nagar PK, et al
    Identification of Immune-Associated Hub Genes Related to the G2/M Checkpoint Pathway in Bladder Cancer Through Integrated Bioinformatics Analysis.
    Cancer Inform. 2026;25:11769351261500680.
    PubMed    
    Abstract available

  190. KUCUKSEN MF, Colak TS, Goger YE, Esen HH, et al
    Unusual Presentation of Metastatic Bladder Cancer: A Case Report of Acrometastasis to the Hand and Review of the Literature.
    Clin Med Insights Arthritis Musculoskelet Disord. 2026.
    PubMed    
    Abstract available

  191. HAN J, Li X, Zhou X, Zhang Y, et al
    Hydrogel-Based Therapies for Bladder Cancer: Intravesical Delivery, Immunomodulation, and Precision.
    Tissue Eng Part B Rev. 2026 Nov 18:19373368261506151.
    PubMed    
    Abstract available

  192. WANG W, Xing Z, Wang B, Zheng S, et al
    A Self-Confined Rotational Hydrogel Chemiluminescence Motor Array for Rapid and Sensitive Detection of Bladder Cancer Biomarkers.
    Anal Chem. 2026;98:33328-33337.
    PubMed    
    Abstract available

  193. LI Y, Yan Y, Zuo L, Dong X, et al
    Unlocking a TP53 mutation-specific vulnerability: the miR-486-3p/CYB561 axis in bladder cancer.
    World J Surg Oncol. 2026;24:434.
    PubMed    
    Abstract available

  194. ZHU J, Pan X, Zhang Z, Gao J, et al
    Retraction notice to "Downregulation of integrin-linked kinase inhibits epithelial-to-mesenchymal transition and metastasis in bladder cancer cells" [Cell. Signal. 24 (2012) 1323-1332].
    Cell Signal. 2026 Nov 18:112992. doi: 10.1016/j.cellsig.2026.112992.
    PubMed    


  195. GILLEY KN, Garness J, Khan A, Materia BR, et al
    Alcohol use reduces the efficacy of anti-PD1 immunotherapy by disrupting antitumor immunity.
    Sci Signal. 2026;19:eaef1375.
    PubMed    
    Abstract available

  196. DONG H, Chen L, Teng X, Shi J, et al
    Disassembly of Extracellular Matrix and Intercellular Adhesion Enables Noninvasive Bladder Cancer Disaggregation.
    ACS Nano. 2026;20:31123-31136.
    PubMed    
    Abstract available

  197. FUJIO K, Higaki A, Miura N, Kurokawa K, et al
    A Case of Confirmed Diagnosis of Wild-Type Transthyretin Cardiac Amyloidosis from a Bladder Cancer Resection Specimen.
    CJC Open. 2026;8:1526-1529.
    PubMed    


  198. LI S, Ding H, Bai Y, Liu H, et al
    [Predictive Performance of an Ultrasound Blood Perfusion Parameter-Based Model for Postoperative Prognosis of Patients With Bladder Cancer].
    Sichuan Da Xue Xue Bao Yi Xue Ban. 2026;57:1514-1520.
    PubMed    
    Abstract available

  199. TAKAHASHI T, Takamatsu K, Igarashi D, Umezawa Y, et al
    Adrenal Insufficiency After Preoperative Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced Bladder Cancer: A Case Report.
    IJU Case Rep. 2026;9:e70292.
    PubMed    
    Abstract available

  200. YAN Y, Wang L, Zhou Y, Wang X, et al
    Preoperative frailty and multidimensional concurrent correlates among older adults scheduled for radical cystectomy: a social ecological model-informed cross-sectional study.
    BMC Urol. 2026;26:295.
    PubMed    
    Abstract available

  201. ROMSA J, Sutherland D, Akincioglu C
    MR Clinics-Nuclear Medicine in Renal, Adrenal, Bladder and Urothelial Malignancies.
    Magn Reson Imaging Clin N Am. 2027;35:63-77.
    PubMed    
    Abstract available

  202. SAINI D, Chaudhary PK, Lhamu T, Chaudhary JK, et al
    Eugenol Suppresses Heavy Metal-Induced Proliferation of Urinary Bladder Cancer Cells Through Modulation of DNA Demethylation and Activation of the Intrinsic Apoptotic Pathway.
    Environ Toxicol. 2026 Nov 16. doi: 10.1002/tox.70209.
    PubMed    
    Abstract available

  203. NAGUMO Y, Kinase S, Nishiyama H
    [Recent Advances in ctDNA and utDNA Research for Bladder Cancer].
    Gan To Kagaku Ryoho. 2026;53:683-688.
    PubMed    
    Abstract available

  204. SINGH P, Plets M, Efsthathiou J, Jhavar SG, et al
    Study Rationale, Enrollment Characteristics, and Central Review of Clinical Stage: The INTACT Randomized Clinical Trial.
    JAMA Netw Open. 2026;9:e2644122.
    PubMed    
    Abstract available

  205. SIGVA H, Sevim M, Korpe K, Atis V, et al
    Machine learning-based prediction of BCG NON-RESPONSE in high-risk NON-muscle-invasive bladder cancer: An exploratory single-centre cohort study.
    Ther Adv Urol. 2026;18:17562872261493691.
    PubMed    
    Abstract available

  206. MANIVASAGAM SS, Sheikhsaran F, Raman JD, Aminsharifi A, et al
    Circulating tumor DNA as a tool for precision management in bladder cancer: A narrative review.
    Ther Adv Urol. 2026;18:17562872261493705.
    PubMed    
    Abstract available

  207. CHAIYADET S, Roblin T, Fauchois A, Temmam S, et al
    Fluke-borne viruses are a risk factor and diagnostic target for diseases caused by carcinogenic trematodes.
    Nat Commun. 2026;17:11707.
    PubMed    
    Abstract available

  208. GHALEHTAKI R, Shariati A, Mehrtabar E, Arshadi MR, et al
    Adding immune checkpoint inhibitors to bladder-preservation therapy in muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Crit Rev Oncol Hematol. 2026;229:105701.
    PubMed    
    Abstract available

  209. ABUSHAMMA F, Abdalrazeq H, Hajjeh O, Algharaba S, et al
    Urinary biomarker-guided surveillance versus standard cystoscopic surveillance for non-muscle-invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trials.
    World J Urol. 2026;44:811.
    PubMed    
    Abstract available

  210. GUO X, Ma Y, He L, Chen Y, et al
    Prognostic Significance of Adverse Histopathological Features in Early-Onset Bladder Urothelial Carcinoma After Radical Cystectomy: A Propensity Score-Matched Analysis.
    Cancer Med. 2026;15:e72500.
    PubMed    
    Abstract available

  211. EKENCI BY, Sari H, Durak HM, Karakoyunlu AN, et al
    Histological Subtypes, Divergent Differentiation, and Neuroendocrine Components in Primary Non-Muscle-Invasive Bladder Cancer Managed with Bladder-Preserving Approaches: A Propensity Score-Matched Study.
    Clin Genitourin Cancer. 2026 Oct 26:102703. doi: 10.1016/j.clgc.2026.102703.
    PubMed    
    Abstract available

  212. XU G, Zhao W, Li Y, Fang S, et al
    The HDAC2/KAT2A-Lamin A lactylation axis regulates tumor progression and chemoresistance in bladder cancer.
    Cancer Lett. 2026;664:218968.
    PubMed    
    Abstract available

  213. SULEJA A, Bret D, Miszczyk M, Dong W, et al
    Efficacy of HER2-targeted therapies in localized urothelial carcinoma: a systematic review and meta-analysis.
    World J Urol. 2026;44:810.
    PubMed    
    Abstract available

  214. LUO Z, Xu D, Wang Z, Wu L, et al
    Charting the landscape of microbiota in bladder cancer: Molecular mechanisms and therapeutic implications.
    Genes Dis. 2026;14:102270.
    PubMed    
    Abstract available

  215. WONG J, Wong R, Hamilton Z, Wang L, et al
    Role of Radical Cystectomy in Metastatic Bladder Cancer.
    J Clin Med. 2026;15:8586.
    PubMed    
    Abstract available

  216. VASILE DF, Mesina M, Mitroi GG, Danila AD, et al
    Preoperative Systemic Inflammatory Indices (SII, SIRI and PIV) Associated with Adverse Histology and 12-Month Recurrence After Transurethral Resection of Non-Muscle-Invasive Bladder Cancer.
    J Clin Med. 2026;15:8536.
    PubMed    
    Abstract available

  217. EL BOUHADDANI S, Albashri A, Almohammadi O, Alamri M, et al
    From Stage to Systems: Integrating Standard Laboratory Markers into Bladder Cancer Prognostic Models.
    Diagnostics (Basel). 2026;16:3486.
    PubMed    
    Abstract available

  218. LAWINSKI J, Franczyk B, Sagr A, Popek K, et al
    Clinical Utility of lncRNAs in Urothelial Carcinoma of the Bladder: Diagnostics, Risk Stratification, and Treatment Guidance.
    Int J Mol Sci. 2026;27:9461.
    PubMed    
    Abstract available

  219. QIN SL, Owusu-Amo B, Miyamoto DT
    Revealing the Invisible: Circulating and Urinary Tumor DNA in Bladder Cancer.
    Cancers (Basel). 2026;18:3566.
    PubMed    
    Abstract available

  220. WANG Y, Zhou X, Li J, Qu H, et al
    Does neoadjuvant or induction systemic therapy modify the association between pelvic lymph node dissection metrics and survival after radical cystectomy for bladder cancer? A systematic review and meta-analysis.
    World J Surg Oncol. 2026;24:427.
    PubMed    
    Abstract available

  221. BI W, Xu L, Ma L, Zhu J, et al
    FOXP2/FABP4 axis promotes bladder cancer aggressiveness by driving lipid metabolic reprogramming to activate FAK/Src signaling.
    Urol Oncol. 2026 Nov 13:S1078-1439(26)00770.
    PubMed    
    Abstract available

  222. YANG C, Li Q, Chen X, Zhang Z, et al
    Retraction of: Circular RNA circRGNEF promotes bladder cancer progression via miR-548/KIF2C axis regulation.
    Aging (Albany NY). 2026;18:1529.
    PubMed    


  223. WEI R, Guo Y, Jin D, Zhu HJ, et al
    Best Evidence for Bladder Function Exercise in Patients With Bladder Cancer Following Orthotopic Neobladder Reconstruction.
    Semin Oncol Nurs. 2026;43:152415.
    PubMed    
    Abstract available

  224. HUMAYUN-ZAKARIA N, Yu M, Goel A, Gordon NS, et al
    Transcriptomic profiling of tropomyosin isoforms in bladder cancer: multi-platform sequencing and experimental validation.
    Sci Rep. 2026;16:37672.
    PubMed    
    Abstract available

  225. STOKKEL LE, Angelino M, Boellaard TN, van de Kamp MW, et al
    Detection of recurrence after surgical treatment for urachal adenocarcinoma: diagnostic yield of cystoscopy, imaging and serum tumor markers.
    World J Urol. 2026;44:803.
    PubMed    
    Abstract available

  226. SHIMODA H, Numao N, Oki R, Urasaki T, et al
    Lymphovascular invasion and nodal positivity may identify candidates for adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma.
    Urol Oncol. 2026;44:931-938.
    PubMed    
    Abstract available

  227. SU D, Li S, Hou J, Chen G, et al
    Preoperative Renal Impairment as an Independent Determinant of Poor Survival After Concomitant Laparoscopic Radical Cystectomy and Nephroureterectomy.
    Ann Surg Oncol. 2026;33:11644-11653.
    PubMed    
    Abstract available

  228. BRIGGS LG, Choudry MM, Nguyen MV, Durant AM, et al
    Prehabilitation for patients undergoing radical cystectomy: Patient selection and targeted interventions.
    Urol Oncol. 2026;44:911-920.
    PubMed    
    Abstract available

  229. ZHANG H, Lv Z, Wang Z, Lu Y, et al
    Postoperative progression-free survival and clinicopathological risk stratification in urachal carcinoma: A multicenter retrospective cohort study.
    Urol Oncol. 2026;44:887-896.
    PubMed    
    Abstract available

  230. PEREZ-LONDONO A, Kaul S, Fleishman A, Konety B, et al
    Performance of the EORTC and CUETO risk prediction models in contemporary patients undergoing transurethral resection of bladder tumor with blue light cystoscopy.
    Urol Oncol. 2026;44:1023-1032.
    PubMed    
    Abstract available

  231. TAN H, Zhang Y, Long Y, Shu L, et al
    CDKL1 facilitates tumorigenesis and metastasis of bladder urothelial carcinoma by activating SIRT1/Wnt/beta-catenin signaling.
    Urol Oncol. 2026;44:1007-1022.
    PubMed    
    Abstract available

  232. DHAWAN D, Sola MF, Nelson JB, Lanman NA, et al
    BRAFV595E mutation detected across the disease spectrum from non-neoplastic urothelium to invasive urothelial carcinoma in dogs.
    J Am Vet Med Assoc. 2026;264.
    PubMed    
    Abstract available

  233. NOMINATO EO, Miranda AARR, Fernandes MEM, Amaral VL, et al
    Intraoperative indocyanine green fluorescence guidance to reduce ureteroenteric anastomotic strictures during robot-assisted radical cystectomy. A systematic review and meta-analysis.
    Urol Oncol. 2026;44:998-1006.
    PubMed    
    Abstract available

  234. OKUMURA G, Yoshida S, Hirose K, Yajima S, et al
    A Bayesian reanalysis of the THOR trial cohort 1 using reconstructed individual patient data: interval-specific effects and clinically interpretable estimands under non-proportional hazards.
    Jpn J Clin Oncol. 2026;56:1437-1442.
    PubMed    
    Abstract available

  235. GU Y, Zhuo H
    Machine learning-driven construction and validation of an intra-tumoral heterogeneity-associated prognostic model for bladder urothelial carcinoma.
    Comput Methods Biomech Biomed Engin. 2026;29:3541-3553.
    PubMed    
    Abstract available

  236. SHIMIZU T, Nagano Y, Morioka Y, Miyashita M, et al
    TIM-3 Up-regulation Is Associated With Altered Cytotoxic Function of Allogeneic Vgamma9Vdelta2 T Cells in Urinary Bladder Cancer.
    Anticancer Res. 2026;46:6017-6027.
    PubMed    
    Abstract available

  237. SANO A, Tamura K, Sakai Y, Kahyo T, et al
    High Ubiquitin-like Protein 3 Expression Is Associated With Prolonged Recurrence-free Survival in Non-muscle-invasive Bladder Cancer.
    Anticancer Res. 2026;46:6249-6263.
    PubMed    
    Abstract available

  238. CHEN HW, Li JR, Wang SS, Yang CK, et al
    Overall Survival After Neoadjuvant Versus Adjuvant Chemotherapy for Invasive Urothelial Carcinoma of the Bladder: A Real-world Multicenter Cohort Study.
    Anticancer Res. 2026;46:6331-6341.
    PubMed    
    Abstract available

  239. SIMARD F, Lacombe MM, Simonyan D, Garneau CA, et al
    Beyond the label 'high-grade': histological heterogeneity as a prognostic marker in Ta non-muscle-invasive bladder cancer.
    BJU Int. 2026 Nov 2. doi: 10.1111/bju.70522.
    PubMed    
    Abstract available

  240. LU H, Zhang Y, Zhao Y, Zhang Y, et al
    Global trends in urological cancers: an analysis of the global burden of disease study 2023.
    BJU Int. 2026;138:1034-1042.
    PubMed    
    Abstract available

  241. ATIQ SO, Anker JF, Miller EJ, Karol AB, et al
    The evolving role of perioperative systemic therapy in bladder cancer.
    Cancer. 2026;132:e70629.
    PubMed    
    Abstract available

  242. ZHONG Y, Li Y, Wang Q, Cai J, et al
    Integrated multi-omics reveals longitudinal metabolic dynamics and reprogramming in bladder cancer.
    Clin Cancer Res. 2026 Nov 6. doi: 10.1158/1078-0432.CCR-26-1201.
    PubMed    
    Abstract available

  243. OSORIO JC, Blanchard L, Yao N, Alam SM, et al
    Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Phase I Trial.
    Clin Cancer Res. 2026 Nov 17. doi: 10.1158/1078-0432.CCR-26-3256.
    PubMed    
    Abstract available

  244. KASAHARA R, Ueki T
    Interpreting International Real-World Survival Outcomes After Avelumab First-Line Maintenance in Advanced Urothelial Carcinoma: An RMST Analysis of Reconstructed Individual Patient Data.
    Int J Urol. 2026;33:e70678.
    PubMed    
    Abstract available

  245. SHAHZAD MH
    Beyond Association: Clarifying the Biological and Clinical Value of Urinary EphA2 in Bladder Cancer.
    Int J Urol. 2026;33:e70697.
    PubMed    


  246. MIYAKE M
    Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer: A Copula-Based Secondary Analysis.
    Int J Urol. 2026;33:e70699.
    PubMed    


  247. TOUGE T, Horiguchi A, Shinchi M, Higuchi M, et al
    Urethroplasty for Anterior Urethral Stricture in Men With Non-Muscle-Invasive Bladder Cancer: Feasibility and Durability of a Pragmatic Recurrence-Free Interval-Oriented Strategy.
    Int J Urol. 2026;33:e70711.
    PubMed    
    Abstract available

  248. KAKITA S, Matsuo T, Otsubo A, Araki K, et al
    Phospho-LATS1/2 Immunoreactivity and Survival in Muscle-Invasive Bladder Cancer: A Quantitative Immunohistochemical Study.
    Int J Urol. 2026;33:e70715.
    PubMed    
    Abstract available

  249. JAABOU M, Dovey Z, Zaytoun O, Awan M, et al
    Predictors of residual tumour and recurrence in high-grade NMIBC: insights from a multicenter re-TURBT cohort.
    Int Urol Nephrol. 2026;58:5215-5221.
    PubMed    
    Abstract available

  250. STROUD M, Talwar R, Bjurlin MA
    The Missing Comparator: Smoking Cessation Cost-Effectiveness in the Era of Novel Bladder Cancer Therapies.
    J Urol. 2026 Oct 28:101097JU0000000000005359. doi: 10.1097/JU.0000000000005359.
    PubMed    


  251. MORALES A, Koti M, Siemens DR
    Golden Anniversary of BCG in Bladder Cancer: Lessons and Opportunities.
    J Urol. 2026 Nov 11:101097JU0000000000005364. doi: 10.1097/JU.0000000000005364.
    PubMed    


  252. ZHANG S, Li T, Li D, Yin Y, et al
    Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial: Erratum.
    J Urol. 2026;216:892.
    PubMed    


  253. JOYCE DD, Sharma V, Ratcliff GE, Barocas DA, et al
    Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy Plus Bacillus Calmette-Guerin for High-Risk Nonmuscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN: Erratum.
    J Urol. 2026;216:889-891.
    PubMed    


  254. TOPCU I, Ozdes AA, Dural B, Yildirim OF, et al
    The CALLY Index as an Independent Predictor of Survival in Bladder Cancer Patients Undergoing Radical Cystectomy: A Multicenter Study.
    Urol Int. 2026 Nov 16:aewag059. doi: 10.1159.
    PubMed    
    Abstract available

  255. NGUYEN SL, Baer BR, Bruno N, Raman JD, et al
    Clinical Implications of Discordant Urinalysis and Urine Culture Findings Before Urologic Surgery.
    Urology. 2026;216:10-16.
    PubMed    
    Abstract available

  256. TALLMAN JE, Hyman MJ, Agarwal PK, Faris SF, et al
    Reply to "Editorial Comment on "Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer.
    Urology. 2026 Nov 18:S0090-4295(26)00729-6. doi: 10.1016/j.urology.2026.
    PubMed    


  257. SOOD A
    Editorial Comment on "Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer".
    Urology. 2026 Nov 13:S0090-4295(26)00721-1. doi: 10.1016/j.urology.2026.
    PubMed    


  258. HAO WP, Lin ZB, Ke L, Liu HJ, et al
    Overexpression of small nucleolar RNA host gene family members predicts poor bladder cancer prognosis: based on a systematic review and meta-analysis.
    BMC Cancer. 2026;26:1324.
    PubMed    
    Abstract available

  259. ZHENG W, Yao C, Wang Z, Zhang C, et al
    The predictive value of PD-1 for the response to immune checkpoint inhibitor therapy in patients with bladder cancer without lymph node metastasis and its association with survival outcomes.
    BMC Cancer. 2026;26:1348.
    PubMed    
    Abstract available

  260. CAO S, Liu M, Wang C, Yang S, et al
    Nonsteroidal anti-inflammatory drug use and site-specific risk of urological cancers: a systematic review and meta-analysis.
    BMC Cancer. 2026;26:1471.
    PubMed    
    Abstract available

  261. ISHIMOTO K, Narita T, Sekine Y, Shinohara M, et al
    Real-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma.
    BMC Cancer. 2026;26:1470.
    PubMed    
    Abstract available

  262. PARVIZIFARA S, Angaji SA, Beikzadeh B, Narouie B, et al
    CD22 and CD79A expression level in bladder cancer patients using bioinformatics tools, RNA-Seq and qRT-PCR validation.
    BMC Cancer. 2026;26:1419.
    PubMed    
    Abstract available

  263. TOBE T, Teishima J, Hara T, Shiraishi Y, et al
    Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model.
    PLoS One. 2026;21:e0361593.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum


;